Drug name - Rocklatan

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9096569 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US8450344 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(7 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9993470 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10882840 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US10532993 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US11021456 AERIE PHARMS INC Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Jul, 2026

(3 years from now)

US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure
Mar, 2034

(11 years from now)

US11197853 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2022
New Combination (NC) Mar 12, 2022

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

Market Authorisation Date: 12 March, 2019

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.005%;EQ 0.02% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in